Team Hewins LLC Has $246,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Team Hewins LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 973 shares of the medical research company’s stock after purchasing an additional 46 shares during the quarter. Team Hewins LLC’s holdings in IQVIA were worth $246,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. AdvisorNet Financial Inc boosted its holdings in IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 95 shares in the last quarter. Rise Advisors LLC bought a new position in shares of IQVIA in the first quarter valued at approximately $31,000. BKM Wealth Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at approximately $32,000. Riverview Trust Co bought a new position in IQVIA in the 1st quarter worth approximately $32,000. Finally, Activest Wealth Management bought a new position in IQVIA in the 4th quarter worth approximately $35,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on IQV shares. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Sunday. Evercore ISI cut their price objective on shares of IQVIA from $250.00 to $230.00 and set an “outperform” rating for the company in a research report on Tuesday. Barclays lowered their target price on shares of IQVIA from $275.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, June 28th. The Goldman Sachs Group began coverage on shares of IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 target price on the stock. Finally, Robert W. Baird lowered their target price on shares of IQVIA from $241.00 to $235.00 and set a “neutral” rating on the stock in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $255.73.

IQVIA Stock Performance

IQV traded up $7.16 during midday trading on Thursday, reaching $219.14. The company had a trading volume of 559,780 shares, compared to its average volume of 1,059,328. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. The stock has a market cap of $39.93 billion, a PE ratio of 28.96, a P/E/G ratio of 1.90 and a beta of 1.49. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The business has a 50-day moving average price of $219.75 and a two-hundred day moving average price of $229.10.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. The company had revenue of $3.74 billion for the quarter, compared to analysts’ expectations of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.